Ultragenyx Pharmaceutical Inc. (RARE): Sunil Agarwal , Chief Medical Officer of Ultragenyx Pharmaceutical Inc. sold 650 shares on Jun 20, 2016. The Insider selling transaction was reported by the company on Jun 21, 2016 to the Securities and Exchange Commission. The shares were sold at $54.16 per share for a total value of $35,204.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 26, 2016, Sunil Agarwal (Chief Medical Officer) sold 650 shares at $66.00 per share price.On May 18, 2016, Emil D Kakkis (President & CEO) sold 20,000 shares at $60.74 per share price.Also, On Dec 18, 2015, Theodore Alan Huizenga (Controller and PAO) sold 1,500 shares at $110.55 per share price.On Dec 14, 2015, Shalini Sharp (CFO & Senior Vice President) sold 12,000 shares at $101.60 per share price.
Shares of Ultragenyx Pharmaceutical Inc (RARE) ended Monday, Jun 20, 2016 session in red amid volatile trading. The shares closed down -0.49 points or -0.89% at $54.5 with 9,78,756 shares getting traded. Post opening the session at $56.28, the shares hit an intraday low of $54.09 and an intraday high of $57.15 and the price vacillated in this range throughout the day. The company has a market cap of $2,127 M and the number of outstanding shares has been calculated to be 3,90,20,576 shares. The 52-week high of Ultragenyx Pharmaceutical Inc is $137.05 and the 52-week low is $49.
Company has been under the radar of several Street Analysts.Ultragenyx Pharmaceutical Inc is Reiterated by Wedbush to Outperform while Lowering the Price Target of the company shares to $ 92 from a previous price target of $99 . The Rating was issued on May 10, 2016.
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification acquisition development and commercialization of products for the treatment of rare and ultra-rare diseases with a focus on serious debilitating genetic diseases. Its pipeline consists of two product categories: biologics including a monoclonal antibody and enzyme replacement therapies and small-molecule substrate replacement therapies. Its products are KRN23 (UX023) rhGUS (UX003) rhPPCA (UX004) Triheptanoin (UX007) and SA-ER (UX001). KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. rhGUS is an intravenous (IV) enzyme replacement therapy for the treatment of mucopolysaccharidosis 7. rhPPCA is an enzyme replacement therapy for galactosialidosis. Triheptanoin is a medium odd-chain triglyceride of seven-carbon fatty acids. SA-ER is for the treatment of hereditary inclusion body myopathy (HIBM).